Please login to the form below

Not currently logged in

PureTech adds potential IBD therapeutic to pipeline after buying out Alivio Therapeutics

Alivio is developing therapeutic candidates for a number of inflammatory disorders

PureTech Health has acquired all remaining shares of its founded entity Alivio Therapeutics, five years after launching the company, adding a number of anti-inflammatory therapeutic candidates to its pipeline as a result.

Alivio is developing therapeutic candidates for a number of inflammatory disorders, including inflammatory bowel disease (IBD).

Now that PureTech has acquired the remaining 22% of outstanding shares  in Alivio, it will fully integrate these candidates into its wholly owned development pipeline.

Alivio’s technology platform can combine a biologic agent and a small molecule drug into a single oral dosage form, potentially offering an enhanced treatment for certain inflammatory diseases by maximising efficacy and minimising toxicity.

Among these candidates is LYT-500, an orally-administered therapeutic candidate currently in development for the treatment of IBD.

LYT-500 is comprised of two active agents, designed to selectively act on the inflamed tissues while reducing their impact on normal tissues. The candidate contains a combination of IL-22 and an anti-inflammatory drug, in a bid to address the two key underlying causes of IBD pathogenesis and progression.

In addition to LYT-500, PureTech will also add LYT-503/IMB-150 to its pipeline, a potential non-opioid treatment for interstitial cystitis or bladder syndrome which is currently being developed in collaboration with Ibrium Therapeutics.

“PureTech founded Alivio alongside leading scientists Jeffrey Karp, professor of medicine at Brigham and Women’s Hospital and Robert Langer, David H. Koch Institute Professor at MIT to pioneer a novel strategy to more effectively treat inflammatory disorders through highly targeted immunomodulation at the site of disease,” said Daphne Zohar, founder and chief executive officer of PureTech.

"This promising approach fits well within our wholly owned pipeline and we will be able to leverage our strength in immunology and related technologies as we progress therapeutic candidates to potentially treat inflammatory diseases,” she added.

Elsewhere in its pipeline, PureTech has therapeutic candidates in various stages of development for the treatment of a range of conditions and diseases, including idiopathic pulmonary fibrosis, respiratory complications and related sequelae of Long COVID, breast cancer-related upper limb secondary lymphedema and metastatic solid tumours.

Article by
Lucy Parsons

17th June 2021

From: Research, Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....